Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
November 05, 2024 09:30 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for...
Non-Hodgkin Lymphoma Therapeutics Market revenue to hit USD 20 Billion by 2036, says Research Nester
March 19, 2024 07:00 ET
|
Research Nester
New York , March 19, 2024 (GLOBE NEWSWIRE) -- The global non-hodgkin lymphoma therapeutics market size is projected to grow at a CAGR of over 8% from 2024 to 2036. The market is expected to garner a...
B-Cell Lymphoma Clinical Trial Pipeline Insights: DelveInsight Evaluates a Robust Pipeline as 160+ Influential Pharma Players to Set Foot in the Domain
May 31, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 31, 2023 (GLOBE NEWSWIRE) -- B-Cell Lymphoma Clinical Trial Pipeline Insights: DelveInsight Evaluates a Robust Pipeline as 160+ Influential Pharma Players to Set Foot in the...
Rhizen Pharmaceuticals S.A. announces initiation of Phase 2 study of RV1001 in dogs with T- or B-cell Lymphoma
September 22, 2015 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. has announced the initiation of Phase 2 study of RV1001, a novel, oral selective inhibitor of PI3K...
MMRGlobal Receives Additional Biotech Patent Protection in U.S., Mexico and Japan for Cancer Vaccines
October 02, 2013 08:35 ET
|
MMRGlobal, Inc.
LOS ANGELES, CA--(Marketwired - Oct 2, 2013) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR"), a leading provider of Personal Health Records (PHRs), MyEsafeDepositBox storage solutions and electronic...
MMRGlobal Receives Cancer Fighting Vaccine Patent in Hong Kong
June 25, 2013 08:35 ET
|
MMRGlobal, Inc.
LOS ANGELES, CA--(Marketwired - Jun 25, 2013) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR") today announced that it has received another biotechnology patent, this one in Hong Kong. The Company has...
MMRGlobal Announces U.S. Patent for Cancer Fighting Anti-CD20 Monoclonal Antibody
April 15, 2013 08:35 ET
|
MMRGlobal, Inc.
LOS ANGELES, CA--(Marketwired - Apr 15, 2013) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR") today announced that the United States Patent and Trademark Office has issued a Notice of Allowance...
MMRGlobal Targets Phase 3 Biotech Companies to Combine Assets With Life Sciences Group
November 19, 2012 08:35 ET
|
MMRGlobal, Inc.
LOS ANGELES, CA--(Marketwire - Nov 19, 2012) - MMRGlobal, Inc. (OTCBB: MMRF) today announced that through its wholly owned subsidiary, MMR Life Sciences Group, the Company plans on exploiting its...
MMRGlobal Issued Biotech Patent to Produce B-Cell Vaccines and Treat Cancer Patients
November 28, 2011 09:28 ET
|
MMRGlobal, Inc.
LOS ANGELES, CA--(Marketwire - Nov 28, 2011) - MMRGlobal, Inc. (OTCBB: MMRF) (www.mmrvideos.com) today announced that it has just been granted a patent protecting methods of making compositions for...